A specific anti‐COVID‐19 BNT162b2 vaccine‐induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients

OBJECTIVES: The very rapidly approved mRNA‐based vaccines against SARS‐CoV‐2 spike glycoprotein, including Pfizer‐BioNTech BNT162b2, are effective in protecting from severe coronavirus disease 2019 (COVID‐19) in immunocompetent population. However, establishing the duration and identifying correlate...

Descripción completa

Detalles Bibliográficos
Autores principales: Severa, Martina, Rizzo, Fabiana, Sinigaglia, Alessandro, Ricci, Daniela, Etna, Marilena Paola, Cola, Gaia, Landi, Doriana, Buscarinu, Maria Chiara, Valdarchi, Catia, Ristori, Giovanni, Riccetti, Silvia, Piubelli, Chiara, Palmerini, Pierangela, Rosato, Antonio, Gobbi, Federico, Balducci, Stefano, Marfia, Girolama Alessandra, Salvetti, Marco, Barzon, Luisa, Coccia, Eliana Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036198/
https://www.ncbi.nlm.nih.gov/pubmed/36969367
http://dx.doi.org/10.1002/cti2.1434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036198/
https://www.ncbi.nlm.nih.gov/pubmed/36969367
http://dx.doi.org/10.1002/cti2.1434

Ejemplares similares